JP2022542543A5 - - Google Patents

Info

Publication number
JP2022542543A5
JP2022542543A5 JP2022502899A JP2022502899A JP2022542543A5 JP 2022542543 A5 JP2022542543 A5 JP 2022542543A5 JP 2022502899 A JP2022502899 A JP 2022502899A JP 2022502899 A JP2022502899 A JP 2022502899A JP 2022542543 A5 JP2022542543 A5 JP 2022542543A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
sequence
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022502899A
Other languages
English (en)
Japanese (ja)
Other versions
JP7748933B2 (ja
JP2022542543A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/102717 external-priority patent/WO2021008610A1/en
Publication of JP2022542543A publication Critical patent/JP2022542543A/ja
Publication of JP2022542543A5 publication Critical patent/JP2022542543A5/ja
Priority to JP2025015341A priority Critical patent/JP7894963B2/ja
Priority to JP2025156914A priority patent/JP2026001061A/ja
Application granted granted Critical
Publication of JP7748933B2 publication Critical patent/JP7748933B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022502899A 2019-07-17 2020-07-17 抗dll3キメラ抗原受容体及びその使用 Active JP7748933B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2025015341A JP7894963B2 (ja) 2019-07-17 2025-01-31 抗dll3キメラ抗原受容体及びその使用
JP2025156914A JP2026001061A (ja) 2019-07-17 2025-09-22 抗dll3キメラ抗原受容体及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019096360 2019-07-17
CNPCT/CN2019/096360 2019-07-17
CN2020090587 2020-05-15
CNPCT/CN2020/090587 2020-05-15
PCT/CN2020/102717 WO2021008610A1 (en) 2019-07-17 2020-07-17 Anti-dll3 chimeric antigen receptors and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2025015341A Division JP7894963B2 (ja) 2019-07-17 2025-01-31 抗dll3キメラ抗原受容体及びその使用
JP2025156914A Division JP2026001061A (ja) 2019-07-17 2025-09-22 抗dll3キメラ抗原受容体及びその使用

Publications (3)

Publication Number Publication Date
JP2022542543A JP2022542543A (ja) 2022-10-05
JP2022542543A5 true JP2022542543A5 (cg-RX-API-DMAC7.html) 2023-07-21
JP7748933B2 JP7748933B2 (ja) 2025-10-03

Family

ID=74210175

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022502899A Active JP7748933B2 (ja) 2019-07-17 2020-07-17 抗dll3キメラ抗原受容体及びその使用
JP2025015341A Active JP7894963B2 (ja) 2019-07-17 2025-01-31 抗dll3キメラ抗原受容体及びその使用
JP2025156914A Pending JP2026001061A (ja) 2019-07-17 2025-09-22 抗dll3キメラ抗原受容体及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2025015341A Active JP7894963B2 (ja) 2019-07-17 2025-01-31 抗dll3キメラ抗原受容体及びその使用
JP2025156914A Pending JP2026001061A (ja) 2019-07-17 2025-09-22 抗dll3キメラ抗原受容体及びその使用

Country Status (9)

Country Link
US (2) US12421292B2 (cg-RX-API-DMAC7.html)
EP (2) EP4527466A3 (cg-RX-API-DMAC7.html)
JP (3) JP7748933B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220035367A (cg-RX-API-DMAC7.html)
CN (4) CN118420777A (cg-RX-API-DMAC7.html)
AU (1) AU2020314509A1 (cg-RX-API-DMAC7.html)
CA (1) CA3146019A1 (cg-RX-API-DMAC7.html)
TW (2) TW202535924A (cg-RX-API-DMAC7.html)
WO (1) WO2021008610A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021180215A1 (en) 2020-03-12 2021-09-16 Nanjing Legend Biotech Co., Ltd. Glypican-2-binding moieties, chimeric antigen receptors and uses thereof
US20240150456A1 (en) * 2021-04-02 2024-05-09 Nanjing Legend Biotech Co., Ltd. Engineered immune cells and uses thereof
CA3230627A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Antigen recognizing receptors targeting dll3 and uses thereof
EP4499680A1 (en) * 2022-03-29 2025-02-05 Allogene Therapeutics, Inc. Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
WO2024006281A2 (en) * 2022-06-28 2024-01-04 Carisma Therapeutics Inc. Switch receptors and modified immune cells
JP2025525496A (ja) * 2022-07-08 2025-08-05 イマジナブ・インコーポレーテッド Dll3抗原結合構築物
US20260061051A1 (en) * 2022-08-26 2026-03-05 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
CN115820698B (zh) * 2022-11-22 2025-01-21 浙江康佰裕生物科技有限公司 含有嵌合抗原受体和嵌合转换开关受体编码基因的融合基因及其应用
CN116004547B (zh) * 2023-03-06 2025-04-25 浙江康佰裕生物科技有限公司 一种辐照car-t细胞及其制备方法与应用
CN121152872A (zh) * 2023-05-10 2025-12-16 南京传奇生物科技有限公司 嵌合抗原受体及其使用方法
KR20260079181A (ko) * 2023-09-26 2026-06-01 레전드 바이오테크 유에스에이, 인크. Dll3 결합 모이어티 및 이의 용도
CN122094981A (zh) 2023-10-16 2026-05-26 上海先博生物科技有限公司 一种靶向δ样配体3的CAR及应用
WO2025201493A1 (zh) * 2024-03-29 2025-10-02 诺纳生物(苏州)有限公司 Dll3结合分子及其用途
WO2025212519A1 (en) * 2024-04-01 2025-10-09 Moonlight Bio, Inc. Dll3 binding proteins and uses thereof
WO2025240849A1 (en) * 2024-05-16 2025-11-20 The Brigham And Women's Hospital, Inc. Trem2 chimeric antigen receptors and uses thereof
WO2026008059A1 (en) * 2024-07-04 2026-01-08 Nanjing Legend Biotech Co., Ltd. Anti-dll3 constructs and uses thereof
WO2026052061A1 (en) * 2024-09-05 2026-03-12 Nanjing Legend Biotech Co., Ltd. Adoptive cell compositions
WO2026051938A1 (en) * 2024-09-05 2026-03-12 Therorna Shanghai Co., Ltd. Circular rna encoding chimeric antigen receptors targeting dll3 and the use thereof
CN119708238B (zh) * 2025-02-27 2025-07-04 昕传生物科技(北京)有限公司 靶向dll3的抗体、嵌合抗原受体及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
MA41613A (fr) 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
TWI793062B (zh) * 2015-07-31 2023-02-21 德商安美基研究(慕尼黑)公司 Dll3及cd3抗體構築體
CN105153315B (zh) * 2015-10-09 2019-04-02 重庆精准生物技术有限公司 免疫抑制受体联合肿瘤抗原嵌合受体及其应用
CA3034691A1 (en) 2016-08-30 2018-03-08 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use for treating viral and other infections
CN108276493B (zh) * 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
JP2020517263A (ja) 2017-04-19 2020-06-18 ユニバーシティ オブ サザン カリフォルニア がんを治療するための組成物及び方法
BR112020005938A2 (pt) 2017-09-27 2020-11-17 University Of Southern California célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso
US20220025037A1 (en) 2018-04-03 2022-01-27 Dragonfly Therapeutics, Inc. Antibody variable domains targeting dll3, and use thereof
CR20200539A (es) 2018-04-10 2021-07-01 Kite Pharma Inc Receptores quiméricos de dll3 y métodos para su uso

Similar Documents

Publication Publication Date Title
US20260078166A1 (en) Anti-dll3 chimeric antigen receptors and uses thereof
JP6669722B2 (ja) Cd3結合ドメイン
JP2025065142A5 (cg-RX-API-DMAC7.html)
JP2022518925A5 (cg-RX-API-DMAC7.html)
JP2024125370A (ja) クローディン18.2結合部分およびその利用
JP2017527275A5 (cg-RX-API-DMAC7.html)
JP2015527070A5 (cg-RX-API-DMAC7.html)
CN111378044B (zh) 抗体融合蛋白、制备方法及其应用
JP2018538277A5 (cg-RX-API-DMAC7.html)
JP2024508672A (ja) 新規抗cd24抗体
US11945878B2 (en) Switch molecule and switchable chimeric antigen receptor
JP2024504162A5 (cg-RX-API-DMAC7.html)
JP2023554467A5 (cg-RX-API-DMAC7.html)
JP7730432B2 (ja) がん治療におけるpd-1シグナル阻害剤との組み合わせによる抗cldn4-抗cd137二重特異性抗体の使用
JP2024539079A5 (cg-RX-API-DMAC7.html)
JP2023549441A5 (cg-RX-API-DMAC7.html)
JP2023535485A (ja) 抗cd22シングルドメイン抗体および治療用コンストラクト
JP2025087939A (ja) がん治療におけるpd-1シグナル阻害剤との組み合わせによる抗tspan8-抗cd3二重特異性抗体の使用
HK40110781A (en) Anti-dll3 chimeric antigen receptors and uses thereof
HK40110214A (en) Anti-dll3 chimeric antigen receptors and uses thereof
HK40098926A (en) Anti-dll3 chimeric antigen receptors and uses thereof
HK40065826A (en) Anti-dll3 chimeric antigen receptors and uses thereof
HK40065826B (en) Anti-dll3 chimeric antigen receptors and uses thereof